Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors

References

• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306. doi:10.1038/nrc3245.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14:717–734. doi:10.1038/nrclinonc.2017.101.
   PubMed Web of Science ®Google Scholar
• Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–2666. doi:10.1056/NEJMoa051424.
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057–1061. doi:10.1126/science.1079490.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330–336. doi:10.1038/ni904.
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–949. doi:10.1038/nm1093.
   PubMed Web of Science ®Google Scholar
• Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27:186–192. doi:10.1200/JCO.2008.18.7229.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964. doi:10.1126/science.1129139.
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782–795. doi:10.1016/j.immuni.2013.10.003.
   PubMed Web of Science ®Google Scholar
• Mina M, Boldrini R, Citti A, Romania P, D’Alicandro V, De Ioris M, Starmann J, Tjwa M, Plate KH, Sültmann H, et al. Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma. Oncoimmunology. 2015;4:e1019981. doi:10.1080/2162402X.2015.1008371.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–330. doi:10.1038/nature21349.
   PubMed Web of Science ®Google Scholar
• Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res: an off J Am Assoc Cancer Res. 2016;22:1865–1874. doi:10.1158/1078-0432.CCR-15-1507.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–461. doi:10.1016/j.ccell.2015.03.001.
   PubMed Web of Science ®Google Scholar
• Zou W, Wolchok JD, Chen L, Dewhirst M, Fan TM, Gustafson DL, Helman LJ, Kastan MB, Knapp DW, Levin WJ, et al. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4. doi:10.1126/scitranslmed.aaf0746.
   PubMed Web of Science ®Google Scholar
• Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276:97–111. doi:10.1111/imr.12520.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69–74. doi:10.1126/science.aaa4971.
   PubMed Web of Science ®Google Scholar
• Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561–584. doi:10.1038/nrd4591.
   PubMed Web of Science ®Google Scholar
• Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell Infiltration and PD-L1. Cancer Res. 2015;75:2139–2145. doi:10.1158/0008-5472.CAN-15-0255.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463–1469. doi:10.1126/science.aaf1490.
   PubMed Web of Science ®Google Scholar
• Buisseret L, Garaud S, de Wind A, Van Den Eynden G, Boisson A, Solinas C, Gu-Trantien C, Naveaux C, Lodewyckx J-N, Duvillier H, et al. Tumor-infiltrating lymphocyte composition, organization and PD-1/PD-L1 expression are linked in breast cancer. Oncoimmunology. 2017;6:e1257452. doi:10.1080/2162402X.2016.1257452.
   PubMed Web of Science ®Google Scholar
• Lin G, Fan X, Zhu W, Huang C, Zhuang W, Xu H, Lin X, Hu D, Huang Y, Jiang K, et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. Oncotarget. 2017;8:83986–83994. doi:10.18632/oncotarget.20233.
   PubMedGoogle Scholar
• Heineman TE, Widman A, Kuan EC, St John M. The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer. Laryngoscope Investig Otolaryngol. 2017;2:99–103. doi:10.1002/lio2.79.
   PubMed Web of Science ®Google Scholar
• Melaiu O, Mina M, Chierici M, Boldrini R, Jurman G, Romania P, D’Alicandro V, Benedetti MC, Castellano A, Liu T, et al. PD-L1 Is a therapeutic target of the bromodomain inhibitor JQ1 and, combined with HLA Class I, a promising prognostic biomarker in neuroblastoma. Clin Cancer Res: an off J Am Assoc Cancer Res. 2017;23:4462–4472. doi:10.1158/1078-0432.CCR-16-2601.
   PubMed Web of Science ®Google Scholar
• Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K, et al. Tumor-Intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 2016;76:6964–6974. doi:10.1158/0008-5472.CAN-16-0258.
   PubMed Web of Science ®Google Scholar
• Shaikh F, Murray MJ, Amatruda JF, Coleman N, Nicholson JC, Hale JP, Pashankar F, Stoneham SJ, Poynter JN, Olson TA, et al. Paediatric extracranial germ-cell tumours. Lancet Oncol. 2016;17:e149–e62. doi:10.1016/S1470-2045(15)00545-8.
   PubMed Web of Science ®Google Scholar
• Olson TA, Murray MJ, Rodriguez-Galindo C, Nicholson JC, Billmire DF, Krailo MD, Dang HM, Amatruda JF, Thornton CM, Arul GS, et al. Pediatric and adolescent extracranial germ cell tumors: the road to collaboration. J Clin Oncol: Off J Am Soc Clin Oncol. 2015;33:3018–3028. doi:10.1200/JCO.2014.60.5337.
   PubMed Web of Science ®Google Scholar
• De Backer A, Madern GC, Pieters R, Haentjens P, Hakvoort-Cammel FG, Oosterhuis JW, Hazebroek FWJ. Influence of tumor site and histology on long-term survival in 193 children with extracranial germ cell tumors. Eur J Pediatr Surg. 2008;18:1–6. doi:10.1055/s-2007-989399.
   PubMed Web of Science ®Google Scholar
• Frazier AL, Hale JP, Rodriguez-Galindo C, Dang H, Olson T, Murray MJ, Amatruda JF, Thornton C, Arul GS, Billmire D, et al. Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States. J Clin Oncol: Off J Am Soc Clin Oncol. 2015;33:195–201. doi:10.1200/JCO.2014.58.3369.
   PubMed Web of Science ®Google Scholar
• Gobel U, Schneider DT, Calaminus G, Jurgens H, Spaar HJ, Sternschulte W, Waag K, Harms D. Multimodal treatment of malignant sacrococcygeal germ cell tumors: a prospective analysis of 66 patients of the German cooperative protocols MAKEI 83/86 and 89. J Clin Oncol: Off J Am Soc Clin Oncol. 2001;19:1943–1950. doi:10.1200/JCO.2001.19.7.1943.
   PubMed Web of Science ®Google Scholar
• De Pasquale MD, Crocoli A, Conte M, Indolfi P, D’Angelo P, Boldrini R, Terenziani M, Inserra A. Mediastinal germ cell tumors in pediatric patients: A report from the italian association of pediatric hematology and oncology. Pediatr Blood Cancer. 2016;63:808–812. doi:10.1002/pbc.25895.
   PubMed Web of Science ®Google Scholar
• Terenziani M, Bisogno G, Boldrini R, Cecchetto G, Conte M, Boschetti L, De Pasquale MD, Biasoni D, Inserra A, Siracusa F, et al. Malignant ovarian germ cell tumors in pediatric patients: the AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) study. Pediatr Blood Cancer. 2017:64:e26568. doi:10.1002/pbc.26568.
   Web of Science ®Google Scholar
• Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, Olson TA, Rogers PC, Colombani P, Rescorla F, Billmire DF, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study–pediatric oncology group 9049 and children’s cancer group 8882. J Clinical Oncol: Off J Am Soc Clin Oncol. 2004;22:2691–2700. doi:10.1200/JCO.2004.08.015.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013;39:74–88. doi:10.1016/j.immuni.2013.06.014.
   PubMed Web of Science ®Google Scholar
• Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy?. Oncoimmunology. 2017;7:e1364828. doi:10.1080/2162402X.2017.1364828.
   PubMed Web of Science ®Google Scholar
• Yakirevich E, Lefel O, Sova Y, Stein A, Cohen O, Izhak OB, Resnick MB. Activated status of tumour-infiltrating lymphocytes and apoptosis in testicular seminoma. J Pathol. 2002;196:67–75. doi:10.1002/path.996.
   PubMed Web of Science ®Google Scholar
• Hadrup SR, Braendstrup O, Jacobsen GK, Mortensen S, Pedersen LO, Seremet T, Andersen MH, Becker JC, Straten PT. Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells. Inter J Cancer. 2006;119:831–838. doi:10.1002/ijc.21894.
   PubMed Web of Science ®Google Scholar
• Cierna Z, Mego M, Miskovska V, Machalekova K, Chovanec M, Svetlovska D, Hainova K, Rejlekova K, Macak D, Spanik S, et al. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors. Ann Oncology: Official Journal Eur Soc Med Oncol. 2016;27:300–305. doi:10.1093/annonc/mdv574.
   PubMed Web of Science ®Google Scholar
• Fankhauser CD, Curioni-Fontecedro A, Allmann V, Beyer J, Tischler V, Sulser T, Moch H, Bode PK. Frequent PD-L1 expression in testicular germ cell tumors. Br J Cancer. 2015;113:411–413. doi:10.1038/bjc.2015.244.
   PubMed Web of Science ®Google Scholar
• Veras E, Kurman RJ, Wang TL, Shih IM. PD-L1 expression in human placentas and gestational trophoblastic diseases. Inter J Gynecol Pathol: off J Inter Society Gynecol Pathologists. 2017;36:146–153. doi:10.1097/PGP.0000000000000305.
   PubMed Web of Science ®Google Scholar
• Chovanec M, Cierna Z, Miskovska V, Machalekova K, Svetlovska D, Kalavska K, Rejlekova K, Spanik S, Kajo K, Babal P, et al. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors. Oncotarget. 2017;8:21794–21805. doi:10.18632/oncotarget.15585.
   PubMedGoogle Scholar
• Kim HR, Ha SJ, Hong MH, Heo SJ, Koh YW, Choi EC, Kim EK, Pyo KH, Jung I, Seo D, et al. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep. 2016;6:36956. doi:10.1038/srep36956.
   PubMed Web of Science ®Google Scholar
• Ye H, Li X, Zheng T, Liang X, Li J, Huang J, Pan Z, Zheng Y. The effect of the immune system on ovarian function and features of ovarian germline stem cells. SpringerPlus. 2016;5:990. doi:10.1186/s40064-016-2390-3.
   PubMedGoogle Scholar
• Elewa YH, Ichii O, Otsuka S, Hashimoto Y, Kon Y. Characterization of mouse mediastinal fat-associated lymphoid clusters. Cell Tissue Res. 2014;357:731–741. doi:10.1007/s00441-014-1889-6.
   PubMed Web of Science ®Google Scholar
• Sackstein R, Schatton T, Barthel SR. T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. Lab Invest. 2017;97:669–697.
   PubMed Web of Science ®Google Scholar
• Viola A, Sarukhan A, Bronte V, Molon B. The pros and cons of chemokines in tumor immunology. Trends Immunol. 2012;33:496–504. doi:10.1016/j.it.2012.05.007.
   PubMed Web of Science ®Google Scholar
• Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009;69:3077–3085. doi:10.1158/0008-5472.CAN-08-2281.
   PubMed Web of Science ®Google Scholar
• Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang L, et al. The ovarian cancer chemokine landscape is conducive to homing of vaccine-primed and CD3/CD28-costimulated T cells prepared for adoptive therapy. Clin Cancer Res: an off J Am Assoc Cancer Res. 2015;21:2840–2850. doi:10.1158/1078-0432.CCR-14-2777.
   PubMed Web of Science ®Google Scholar